Latest news with #ModernaInc
Bloomberg
01-08-2025
- Business
- Bloomberg
Moderna's Loss Narrows After Cost-Cutting Efforts Take Hold
By Updated on Save Moderna Inc. 's second-quarter loss was narrower than Wall Street expected as the struggling biotech company cuts costs to offset waning sales of its Covid shot. The net loss shrank to $2.13 a share, compared with a loss of $3.33 a year ago.
Bloomberg
31-07-2025
- Business
- Bloomberg
Moderna to Cut 10% of Staff to Offset Slowing Covid Business
Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline. In a note to employees, Chief Executive Officer Stéphane Bancelsaid the company was 'aligning our cost structure to the realities of our business.'
Time of India
10-07-2025
- Health
- Time of India
Moderna's COVID vaccine gets full US approval for at-risk children aged 6 months and older
US regulators have granted Moderna Inc. full approval for its COVID-19 vaccine, Spikevax, for children aged 6 months through 11 years, but only for those at increased risk from the virus. Tired of too many ads? go ad free now The move marks a shift in federal policy under Health and Human Services Secretary Robert F. Kennedy Jr., who has led a controversial effort to scale back universal access to pediatric COVID shots. The Food and Drug Administration's decision, announced Thursday, means that healthy children in this age group will no longer have routine access to the vaccine unless it is prescribed off-label. Moderna's shares rose more than 4% in early trading in New York following the announcement. Under emergency use authorization during the pandemic, COVID-19 vaccines from Moderna and Pfizer were made widely available to all children. But Kennedy, a longtime vaccine skeptic, has reversed course. In 2021, he petitioned the FDA to revoke temporary approval for children's vaccines, citing low risk of severe illness in healthy children. Now, the vaccine's full approval ensures it remains available for high-risk kids, but also restricts broader access. What are the risks of SPIKEVAX? For most people, getting the SPIKEVAX COVID-19 vaccine is safe and simple. But like any vaccine, there are some rare risks you should know about. There's a very small chance of having a serious allergic reaction, usually within a few minutes to an hour after the shot. That's why your doctor or nurse may ask you or your child to wait for a short time after getting vaccinated—just to be safe. As per the official website of Moderna, signs of a serious allergic reaction may include: Difficulty breathing Swelling of the face or throat A fast or racing heartbeat A rash all over the body Dizziness or weakness In rare cases, some people—mostly boys and young men between 12 and 24 years old—have developed myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining around the heart) after getting an mRNA COVID-19 vaccine like SPIKEVAX. Tired of too many ads? go ad free now If you or your child experiences any of the following symptoms within two weeks of the vaccine, it's important to see a doctor right away: Chest pain Shortness of breath A fast, fluttering, or pounding heartbeat In children, signs to watch for can include chest pain, shortness of breath, pounding heartbeat, fainting, being unusually tired or irritable, poor feeding, stomach pain, vomiting, or cool, pale skin. What are the possible side effects of SPIKEVAX? Common side effects around the injection site: pain or tenderness, redness, swelling or firmness, and swollen lymph nodes in the same arm or sometimes in the groin General side effects: feeling tired or sleepy, headache, muscle or joint pain, chills or fever, nausea or vomiting, rash, irritability or crying (especially in young children) and loss of appetite. In some cases, people have also reported fainting or febrile seizures (seizures caused by a fever). While these are less common, it's helpful to be aware of them.
The Hill
30-06-2025
- Health
- The Hill
Experimental Moderna flu shot more effective than approved vaccine, company says
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company's mRNA-1010 flu vaccine's efficacy was nearly 27 percent higher for adults 50 and older than a currently available shot. The shot also showed strong efficacy against each of the major influenza strains in the shot including A/H1N1, A/H3N2 and the B/Victoria lineages. Efficacy appeared consistently strong across age groups, flu vaccination status and among people with various risk factors, Moderna said in a statement. The trial enrolled more than 40,800 adults 50 and older from 11 countries. 'The severity of this past flu season underscores the need for more effective vaccines,' said Stephane Bancel, chief executive officer of Moderna. 'An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.' Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the CDC. At least 600,000 Americans were hospitalized last year due to flu-related illness, agency data show. According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work After consulting the Food and Drug Administration, Moderna withdrew its application last month for a dual flu and COVID-19 vaccine for adults 50 years old and older. Moderna plans to resubmit the application for the combination vaccine with the new data, according to CNBC. The company also plans to submit the data on the mRNA-1010 shot to U.S. regulators this year.
Bloomberg
30-06-2025
- Business
- Bloomberg
Moderna's Flu Vaccine Hits Goal, Paving Way for Combo Shot
By Updated on Save Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines. The shot's efficacy was 27% higher than a licensed influenza vaccine in adults 50 years and older, the company said in a statement Monday. The trial enrolled more than 40,000 adults across 11 countries.
